Pinealon vs Exenatide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Pinealon
Pinealon is a short synthetic peptide developed from research on the pineal gland. It has shown neuroprotective and cognitive-enhancing properties in animal studies.
Full details →Exenatide
Exenatide was the first GLP-1 receptor agonist approved in the US, derived from a compound found in Gila monster saliva. Available as Byetta (twice daily) and Bydureon (once weekly extended-release).
Full details →Side-by-Side Comparison
| Aspect | Pinealon | Exenatide |
|---|---|---|
| Mechanism | Penetrates cell membranes and interacts with DNA to regulate gene expression related to neuronal survival and function. May support pineal gland function and melatonin production. | Synthetic version of exendin-4, which activates GLP-1 receptors to enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and promote satiety. |
| Typical Dosage | Typical dosing: 10-20mg daily, taken in divided doses. Often used in cycles of 10-20 days. | Byetta: 5mcg twice daily for 1 month, then 10mcg twice daily. Bydureon: 2mg subcutaneously once weekly. |
| Administration | Can be taken orally (capsules) or sublingually. Best absorbed on an empty stomach. Often combined with other neuroprotective peptides. | Byetta: Inject within 60 minutes before morning and evening meals. Bydureon: Any time of day, with or without meals. Do not mix with insulin in same syringe. |
| Side Effects | Generally well-tolerated. Limited reported side effects. May affect sleep patterns initially. | Nausea (especially initially), vomiting, diarrhea, dizziness, headache, and injection site reactions (particularly with Bydureon). |
| Best For |